190 related articles for article (PubMed ID: 22841441)
1. Bezafibrate can be a new treatment option for mitochondrial fatty acid oxidation disorders: evaluation by in vitro probe acylcarnitine assay.
Yamaguchi S; Li H; Purevsuren J; Yamada K; Furui M; Takahashi T; Mushimoto Y; Kobayashi H; Hasegawa Y; Taketani T; Fukao T; Fukuda S
Mol Genet Metab; 2012 Sep; 107(1-2):87-91. PubMed ID: 22841441
[TBL] [Abstract][Full Text] [Related]
2. Effect of heat stress and bezafibrate on mitochondrial beta-oxidation: comparison between cultured cells from normal and mitochondrial fatty acid oxidation disorder children using in vitro probe acylcarnitine profiling assay.
Li H; Fukuda S; Hasegawa Y; Kobayashi H; Purevsuren J; Mushimoto Y; Yamaguchi S
Brain Dev; 2010 May; 32(5):362-70. PubMed ID: 19589653
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of bezafibrate on fibroblasts of glutaric acidemia type II patients evaluated using an in vitro probe acylcarnitine assay.
Yamada K; Kobayashi H; Bo R; Purevsuren J; Mushimoto Y; Takahashi T; Hasegawa Y; Taketani T; Fukuda S; Yamaguchi S
Brain Dev; 2017 Jan; 39(1):48-57. PubMed ID: 27591119
[TBL] [Abstract][Full Text] [Related]
4. Carnitine-acylcarnitine translocase deficiency: Two neonatal cases with common splicing mutation and in vitro bezafibrate response.
Vatanavicharn N; Yamada K; Aoyama Y; Fukao T; Densupsoontorn N; Jirapinyo P; Sathienkijkanchai A; Yamaguchi S; Wasant P
Brain Dev; 2015 Aug; 37(7):698-703. PubMed ID: 25459972
[TBL] [Abstract][Full Text] [Related]
5. Characterization of L-aminocarnitine, an inhibitor of fatty acid oxidation.
Chegary M; Te Brinke H; Doolaard M; Ijlst L; Wijburg FA; Wanders RJ; Houten SM
Mol Genet Metab; 2008 Apr; 93(4):403-10. PubMed ID: 18077198
[TBL] [Abstract][Full Text] [Related]
6. Bezafibrate increases very-long-chain acyl-CoA dehydrogenase protein and mRNA expression in deficient fibroblasts and is a potential therapy for fatty acid oxidation disorders.
Djouadi F; Aubey F; Schlemmer D; Ruiter JP; Wanders RJ; Strauss AW; Bastin J
Hum Mol Genet; 2005 Sep; 14(18):2695-703. PubMed ID: 16115821
[TBL] [Abstract][Full Text] [Related]
7. Heat stress deteriorates mitochondrial beta-oxidation of long-chain fatty acids in cultured fibroblasts with fatty acid beta-oxidation disorders.
Li H; Fukuda S; Hasegawa Y; Purevsuren J; Kobayashi H; Mushimoto Y; Yamaguchi S
J Chromatogr B Analyt Technol Biomed Life Sci; 2010 Jun; 878(20):1669-72. PubMed ID: 20207594
[TBL] [Abstract][Full Text] [Related]
8. Bezafibrate in skeletal muscle fatty acid oxidation disorders: a randomized clinical trial.
Ørngreen MC; Madsen KL; Preisler N; Andersen G; Vissing J; Laforêt P
Neurology; 2014 Feb; 82(7):607-13. PubMed ID: 24453079
[TBL] [Abstract][Full Text] [Related]
9. A novel functional assay for simultaneous determination of total fatty acid beta-oxidation flux and acylcarnitine profiling in human skin fibroblasts using (2)H(31)-palmitate by isotope ratio mass spectrometry and electrospray tandem mass spectrometry.
Law LK; Tang NL; Hui J; Ho CS; Ruiter J; Fok TF; Wanders RJ; Lam CW
Clin Chim Acta; 2007 Jul; 382(1-2):25-30. PubMed ID: 17442290
[TBL] [Abstract][Full Text] [Related]
10. Intracellular in vitro probe acylcarnitine assay for identifying deficiencies of carnitine transporter and carnitine palmitoyltransferase-1.
Purevsuren J; Kobayashi H; Hasegawa Y; Yamada K; Takahashi T; Takayanagi M; Fukao T; Fukuda S; Yamaguchi S
Anal Bioanal Chem; 2013 Feb; 405(4):1345-51. PubMed ID: 23143007
[TBL] [Abstract][Full Text] [Related]
11. Peroxisome proliferator activated receptor delta (PPARdelta) agonist but not PPARalpha corrects carnitine palmitoyl transferase 2 deficiency in human muscle cells.
Djouadi F; Aubey F; Schlemmer D; Bastin J
J Clin Endocrinol Metab; 2005 Mar; 90(3):1791-7. PubMed ID: 15613406
[TBL] [Abstract][Full Text] [Related]
12. Peroxisomes contribute to the acylcarnitine production when the carnitine shuttle is deficient.
Violante S; Ijlst L; Te Brinke H; Koster J; Tavares de Almeida I; Wanders RJ; Ventura FV; Houten SM
Biochim Biophys Acta; 2013 Sep; 1831(9):1467-74. PubMed ID: 23850792
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of Metabolic Defects in Fatty Acid Oxidation Using Peripheral Blood Mononuclear Cells Loaded with Deuterium-Labeled Fatty Acids.
Yuasa M; Hata I; Sugihara K; Isozaki Y; Ohshima Y; Hara K; Tajima G; Shigematsu Y
Dis Markers; 2019; 2019():2984747. PubMed ID: 30881520
[TBL] [Abstract][Full Text] [Related]
14. Exposure to resveratrol triggers pharmacological correction of fatty acid utilization in human fatty acid oxidation-deficient fibroblasts.
Bastin J; Lopes-Costa A; Djouadi F
Hum Mol Genet; 2011 May; 20(10):2048-57. PubMed ID: 21378393
[TBL] [Abstract][Full Text] [Related]
15. Management and diagnosis of mitochondrial fatty acid oxidation disorders: focus on very-long-chain acyl-CoA dehydrogenase deficiency.
Yamada K; Taketani T
J Hum Genet; 2019 Feb; 64(2):73-85. PubMed ID: 30401918
[TBL] [Abstract][Full Text] [Related]
16. Correction of fatty acid oxidation in carnitine palmitoyl transferase 2-deficient cultured skin fibroblasts by bezafibrate.
Djouadi F; Bonnefont JP; Thuillier L; Droin V; Khadom N; Munnich A; Bastin J
Pediatr Res; 2003 Oct; 54(4):446-51. PubMed ID: 12840153
[TBL] [Abstract][Full Text] [Related]
17. Bezafibrate activation of PPAR drives disturbances in mitochondrial redox bioenergetics and decreases the viability of cells from patients with VLCAD deficiency.
Lund M; Andersen KG; Heaton R; Hargreaves IP; Gregersen N; Olsen RKJ
Biochim Biophys Acta Mol Basis Dis; 2021 Jun; 1867(6):166100. PubMed ID: 33549744
[TBL] [Abstract][Full Text] [Related]
18. Carnitine palmitoyltransferase 2 and carnitine/acylcarnitine translocase are involved in the mitochondrial synthesis and export of acylcarnitines.
Violante S; Ijlst L; Te Brinke H; Tavares de Almeida I; Wanders RJ; Ventura FV; Houten SM
FASEB J; 2013 May; 27(5):2039-44. PubMed ID: 23322164
[TBL] [Abstract][Full Text] [Related]
19. Deuterated palmitate-driven acylcarnitine formation by whole-blood samples for a rapid diagnostic exploration of mitochondrial fatty acid oxidation disorders.
Dessein AF; Fontaine M; Dobbelaere D; Mention-Mulliez K; Martin-Ponthieu A; Briand G; Vamecq J
Clin Chim Acta; 2009 Aug; 406(1-2):23-6. PubMed ID: 19422814
[TBL] [Abstract][Full Text] [Related]
20. Acylcarnitine profiles in fibroblasts from patients with respiratory chain defects can resemble those from patients with mitochondrial fatty acid beta-oxidation disorders.
Sim KG; Carpenter K; Hammond J; Christodoulou J; Wilcken B
Metabolism; 2002 Mar; 51(3):366-71. PubMed ID: 11887175
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
